Gabapentin oral solution 50 mg/mL AEMPS

Oral solution: Gabapentin oral solution 50 mg/mL AEMPS. Additional appearance criteria are not established by the specific text reviewed. ^[1]

Antiepileptic; use in neuropathic pain depends on the appropriate clinical indication. ^[1]

pH 6.5–8 ^[1]

For the finished product the source specifies:
Amber glass screw-cap bottle, 2–8 °C; protect from light. ^[1]

No oxidative stability study of the finished mixture or inert-atmosphere requirement is provided. Use the source container. ^[1]

Component of base CGR-ES-003: Methyl Parahydroxybenzoate: JP classifies the corresponding pure raw material as slightly soluble in water.
Component of base CGR-ES-003: Propyl Parahydroxybenzoate: JP classifies the corresponding pure raw material as very slightly soluble in water.
Component of base CGR-ES-003: Sucrose: JP classifies the corresponding pure raw material as very soluble in water. ^{[6], [7], [8], [9]}

No numerical relative-humidity limit is given for the finished product. Prevent raw-material wetting and condensation entering the container. ^[1]

For the finished product the source specifies:
Amber glass screw-cap bottle, 2–8 °C; protect from light. ^[1]

Specification of this preparation, not a demonstrated stability range:
pH 6.5–8 ^[1]

No complete compatibility test with added actives or alternative excipients is provided. Substitutions require separate evidence. ^[1]

Identity and weighing basis:
• Gabapentin: 5 g.
• Sodium saccharin: 100 mg.
• Preserved water without propylene glycol AEMPS: 50 mL.
The specified chemical forms/grades belong to the exact source formula.
Component of base CGR-ES-003: Methyl Parahydroxybenzoate: raw-material water solubility is classified as slightly soluble by JP.
Component of base CGR-ES-003: Propyl Parahydroxybenzoate: raw-material water solubility is classified as very slightly soluble by JP.
Component of base CGR-ES-003: Sucrose: raw-material water solubility is classified as very soluble by JP. ^{[1], [6], [7], [8], [9]}

Clean long-sleeved laboratory clothing, hair covering and gloves during handling; change gloves after contamination or damage. ^{[1], [2], [3]}

Reference batch: 100 mL. First ingredient: Gabapentin, 5 g. Independently check chemical form, units and every scale conversion before weighing.
Check complete dissolution and crystallisation at the selected temperature. Calculate dose volume from the exact mg/mL, not the starting tablet or stock strength. Supply a suitable oral syringe.
For the local assessment record quantity per preparation, work frequency, duration of open handling, potential exposure routes and effectiveness of controls. These are assessment inputs; no fictitious final risk score is assigned.
Release checkpoint: confirm final volume or mass at the reference temperature, intended clarity or dispersion, and specified container/closure. Do not equate grams and millilitres without a justified density. ^{[1], [11], [13]}

Before mixing: verify each ingredient’s chemical form and lot, record theoretical amounts and check equipment cleanliness. Follow the temperatures and addition sequence in the procedure below.
SEFH describes continuous stirring for at least 15 minutes and pH 6.5–8.0 for this gabapentin 50 mg/mL formula. ^{[1], [3], [4]}

Period reported by source: 60 days; 30 days in use.
This duration is a specific formulary/source instruction. This review did not verify a complete primary study establishing chemical, physical and microbiological extension for the same finished formulation.
Selected general rule: up to 35 days for an aqueous form appropriately preserved in its final composition and pH. Use 20–25 °C, or 2–8 °C only where permitted/required by the source and compatible with the dosage form. A preservative name is insufficient if it is diluted, inactivated or partitioned into another phase.
The reference-policy ceiling in this edition is the shorter of the source period above and the general ceiling. Extension needs matching active/excipients/strength, container, temperature, a stability-indicating method and the required microbiological evidence for aqueous extension. An applicable official USP–NF compounded monograph is assessed separately in its complete text.
Use-by date = the earliest allowed date from preparation plus selected period, ingredient expiries and any shorter supported limit. In-use dating never extends overall BUD. Complete the actual date for the batch after the required checks.
A default is a conservative dating limit, not experimental proof of batch stability. Its category depends on final composition, preservation and permitted temperatures. Water percentage or loss on drying does not determine aw. Document using SOP-014/F-006; use SOP-017/F-012 for specific aw evidence.
USP clarification: aw measurement is not required for every nonsterile preparation. Category assignment may use the exact composition and relevant representative examples; an uncertain or borderline formulation is best assessed by a suitable specific measurement. This edition contains no measured aw or released batch. The final preparation generally must not outlast the remaining BUD of its compounded bases/intermediates. An exception requires specific justification that physical, chemical and microbiological quality is not adversely affected. Record the final limit, intermediate preparation dates and their actual expiry dates separately.
Closed/in-use distinction: this edition’s closed-container reference ceiling is 35 days subject to its stated prerequisites. After opening use no longer than 30 days and never beyond the previously assigned overall expiry. Opening does not restart the overall BUD. ^{[1], [4], [5], [10], [12], [15]}

Preserved water without propylene glycol AEMPS: CGR-ES-002
Preserved syrup 84% w/v AEMPS: CGR-ES-003
A resolved and released EX029 / CGR-ES-003 base is required. ^[1]

Balance with suitable minimum weight, mortar/pestle or homogeniser, mixing vessels, spatulas, thermometer for heated processes and volumetric equipment for mL quantities.
Calibrated pH meter and suitable check buffers. ^[1]

Dissolve active and saccharin in water with vigorous stirring for at least 15 min. Make up with syrup, mix and check pH. ^[1]

Prepare base CGR-ES-003 using the exact published ratios and a theoretical 1000.75 g input basis. Use the required quantity only after density and pH checks. The finished preparation retains its own preservation, packaging and BUD assessment. ^[14]

Amber glass screw-cap bottle, 2–8 °C; protect from light. ^[1]

pH 6.5–8
Record the method, acceptance criterion, actual result and reviewer separately in F-005. A critical specification failure requires quarantine and investigation under SOP-015; retesting needs justification. ^{[1], [13]}

Amber glass screw-cap bottle, 2–8 °C; protect from light. ^[1]

Dispense the exact prescribed strength. For liquids use a suitable graduated oral syringe; record dose and frequency from the prescription. ^[1]

Gabapentin oral solution 50 mg/mL AEMPS
Oral use
Quantity: ____ Batch: ____
Prepared: ____ Use by: ____
Patient / dose / frequency: ____
Storage: Amber glass screw-cap bottle, 2–8 °C; protect from light.
Temperature for this batch BUD: ____ ^[1]

The numeric value is a literature reference ceiling subject to its specific conditions. No actual batch BUD has been assigned and no aw measurements have been produced. The exact formula, prerequisites, container, storage and quality evidence require approval for the actual application. The BUD clock starts when compounding begins. Use the shortest applicable supported limit and assess in-use dating separately. USP categories are a technical framework and are not presented as Greek legislation.